



TEXAS A&M UNIVERSITY
Clinical Science &
Translational Research

Grand Rounds



BINCY P. ABRAHAM, MD, MS, AGAF, FACP

**Professor of Clinical
Medicine, Houston Methodist
Academic Institute;
Professor of Clinical
Medicine, Weill Cornell
Medical College; Adjunct
Associate Professor of
Internal Medicine, Texas
A&M University College of
Medicine; Director,
Gastroenterology Fellowship
Program, Houston
Methodist; Distinguished
Professor and Director,
Underwood Center –
Fondren Inflammatory
Bowel Disease Program**

**Next Grand Rounds:
November 2, 2021 –William
Zoghbi, MD; Elkins Family
Distinguished Chair in
Cardiac Health, DeBaakey
Heart & Vascular Center;
Chair, Dept. of Cardiology;
Houston Methodist**

This event will be recorded and
available online at
cstrinstitute.tamhsc.edu

*CME credit given ONLY for
attendance at live event.*

“Impact of Biologics and Small Molecules in Inflammatory Bowel Disease”

**Tuesday, October 5, 2021
12:00–1:00 pm**

Via ZOOM:

<https://tamu.zoom.us/j/99304719171?pwd=VHg0eGV2eFRPcDdVbVJZcm9vbnRoUT09>

Meeting ID: 993 0471 9171

Password: 496960

Dial in: 1 346 248 7799 or 1 888 788 0099 or 1 877 853 5247

OBJECTIVES: Upon completion of this activity, the participant should be able to:
1) Describe the etiology and clinical signs and symptoms of inflammatory bowel
disease and 2) Discuss the impact that medical therapy, especially biologics and
small molecules, have had in the treatment of inflammatory bowel disease.

ACCREDITATION: Texas A&M University College of Medicine is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.

DESIGNATION: Texas A&M University College of Medicine designates this live
activity for a maximum of *1 AMA PRA Category 1 Credit™*. Physicians should claim
only credit commensurate with the extent of their participation in the activity.

DISCLOSURE: Bincy Abraham, MD, MS, faculty for this educational activity, has
disclosed that she has served as a consultant and/or speaker for the following
ineligible companies whose primary business is producing, marketing, selling, re-
selling, or distributing healthcare products used by or on patients: Abbvie, Janssen,
Pfizer, Takeda, Medtronic, Samsung, Lilly, Ferring, and BMS.

All of the relevant financial relationships listed have been mitigated.

The planners for this educational activity have no relevant financial relationship(s)
to disclose with ineligible companies whose primary business is producing,
marketing, selling- re-selling, or distributing healthcare products used by or on
patients.

Physicians claiming CME credit should submit an evaluation online at
[https://med.catalog.instructure.com/courses/cstr-grand-rounds-oct-2021-
impact-of-biologics-small-molecules-in-inflammatory-bowel-disease-live](https://med.catalog.instructure.com/courses/cstr-grand-rounds-oct-2021-impact-of-biologics-small-molecules-in-inflammatory-bowel-disease-live)

Medical students claiming course credit should complete the evaluation form at
https://tamuhsc.co1.qualtrics.com/jfe/form/SV_5ut48F7MK7AAUHc

For further information, email CSTR@tamu.edu.